股本结构
单位：万股
| 公告日期 | 2026-03-05 | 2026-02-03 | 2026-02-03 | 2026-01-06 | 2025-12-12 | 2025-12-01 |
|---|---|---|---|---|---|---|
| 证券总股本 | 142.80 | 110.00 | 2780.00 | 2777.93 | 2664.96 | 3320.33 |
| 普通股本 | 142.80 | 110.00 | 2780.00 | 2777.93 | 2664.96 | 3320.33 |
| 优先股 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 其他 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 变动日期 | 2026-03-04 | 2026-02-06 | 2026-02-03 | 2025-12-30 | 2025-12-08 | 2025-11-28 |
注释：中概股证券总股本=普通股股本/
存托凭证比例
历史变动
| 公告日期 | 变动后普通股本（万股） | 变动后优先股（万股） | 变动原因 | 变动日期 |
|---|---|---|---|---|
| 2026-03-05 | 142.80 | 未披露 | 定期报告 | 2026-03-04 |
| 2026-02-03 | 110.00 | 未披露 |
更多>>
a 1-for-25 reverse stock split of its common stock
|
2026-02-06 |
| 2026-02-03 | 2780.00 | 未披露 | 定期报告 | 2026-02-03 |
| 2026-01-06 | 2777.93 | 未披露 | 定期报告 | 2025-12-30 |
| 2025-12-12 | 2664.96 | 未披露 | 定期报告 | 2025-12-08 |
| 2025-12-01 | 3320.33 | 未披露 |
更多>>
The underwriter exercised the warrants to cause the company to issue 9,215,675 shares of common stock
|
2025-11-28 |
| 2025-11-13 | 2398.76 | 未披露 | 定期报告 | 2025-11-07 |
| 2025-11-13 | 2383.64 | 未披露 |
更多>>
From June 30, 2025 to September 30, 2025
Equity-based compensation – stock issuances to a vendor and vesting to employee
Net proceeds from sale of common stock
Exercise of warrants, net of expenses
|
2025-09-30 |
| 2025-08-13 | 2182.82 | 未披露 | 定期报告 | 2025-08-08 |
| 2025-08-01 | 2161.46 | 未披露 | 定期报告 | 2025-07-28 |
| 2025-08-13 | 2153.47 | 未披露 |
更多>>
From March 31, 2025 to June 30, 2025
Net proceeds from sale of common stock
Exercise of warrants, net of expenses
|
2025-06-30 |
| 2025-06-18 | 1577.59 | 未披露 |
更多>>
Common Stock offered 5,341,200 shares by the company
|
2025-06-18 |
| 2025-06-13 | 1043.47 | 未披露 | 定期报告 | 2025-06-11 |
| 2025-05-30 | 871.97 | 未披露 | 定期报告 | 2025-05-28 |
| 2025-05-14 | 790.07 | 未披露 | 定期报告 | 2025-05-13 |
| 2025-05-14 | 664.96 | 未披露 |
更多>>
From January 1, 2025 to March 31, 2025
Equity-based compensation - stock issuances to a vendor and vesting to employee
Net proceeds from sale of common stock
|
2025-03-31 |
| 2025-03-04 | 657.46 | 未披露 | 定期报告 | 2025-02-28 |
| 2025-03-04 | 647.46 | 未披露 |
更多>>
From December 31, 2023 to December 31, 2024
Stock-based compensation, common stock issued for services
Issuance of commitment shares
Sale of common stock
Warrant exercises
|
2024-12-31 |
| 2024-12-20 | 647.46 | 未披露 | 定期报告 | 2024-12-17 |
| 2024-11-13 | 640.58 | 未披露 |
更多>>
From June 30, 2024 to September 30, 2024
Equity-based compensation – stock issuances to consultants and employees
Sale of common stock, net of transaction costs
|
2024-09-30 |
| 2024-09-27 | 640.58 | 未披露 | 定期报告 | 2024-09-26 |
| 2024-08-13 | 640.34 | 未披露 | 定期报告 | 2024-08-12 |
| 2024-08-13 | 429.37 | 未披露 |
更多>>
From March 31, 2024 to June 30, 2024
Sale of common stock, net of transaction costs
|
2024-06-30 |
| 2024-05-14 | 423.33 | 未披露 | 定期报告 | 2024-05-13 |
| 2024-05-14 | 405.49 | 未披露 |
更多>>
From December 31, 2023 to March 31, 2024
Exercise of warrants
|
2024-03-31 |
| 2024-04-01 | 405.49 | 未披露 | 定期报告 | 2024-03-29 |
| 2024-04-01 | 166.34 | 未披露 |
更多>>
From December 31, 2022 to December 31, 2023
Issuance of commitment shares
Redemption of fractional shares
Stock-based compensation, common stock issued for services
Warrant exercises
Sale of common stock
|
2023-12-31 |
| 2023-11-14 | 121.80 | 未披露 |
更多>>
From June 30, 2023 to September 30, 2023
Redemption of fractional shares
Sale of common stock, net of transaction costs
|
2023-09-30 |
| 2023-08-21 | 121.80 | 未披露 | 定期报告 | 2023-08-18 |
| 2023-08-04 | 120.00 | 未披露 |
更多>>
Adial Pharmaceuticals, Inc. announced that it will effect a 1-for-25 reverse stock split (“reverse split”) of its common stock, par value $0.001 per share (“Common Stock”), that will become effective on August 4, 2023 at 11:59 p.m. Eastern Time.
|
2023-08-07 |
| 2023-06-23 | 2994.20 | 未披露 | 定期报告 | 2023-06-20 |
| 2023-05-12 | 2851.66 | 未披露 |
更多>>
From December 31, 2022 to March 31, 2023
Sale of common stock, net of transaction costs
|
2023-03-31 |
| 2023-02-24 | 2851.66 | 未披露 |
更多>>
common stock offered 1,829,269 shares by the company
|
2023-02-24 |
| 2023-03-30 | 2668.73 | 未披露 |
更多>>
From December 31, 2021 to December 31, 2022
Warrant exercises
Sale of common stock
Stock-based compensation, common stock issued for services
|
2022-12-31 |
| 2022-09-01 | 2685.40 | 未披露 | 定期报告 | 2022-08-18 |
| 2022-08-15 | 2585.40 | 未披露 |
更多>>
From March 31, 2022 to June 30, 2022
Equity-based compensation - stock issuances to consultants and employees
Warrants exercised
|
2022-06-30 |
| 2022-05-16 | 2378.90 | 未披露 | 定期报告 | 2022-05-13 |
| 2022-05-16 | 2371.90 | 未披露 |
更多>>
From December 31, 2021 to March 31, 2022
Equity-based compensation - stock issuances to consultants and employees
Sale of common stock and warrants, net of transaction costs
|
2022-03-31 |
| 2022-02-25 | 2371.90 | 未披露 | 定期报告 | 2022-02-23 |
| 2022-02-15 | 2513.40 | 未披露 |
更多>>
1.Securities offered by 2,322,250 shares of Common Stock
2.The number of shares of Common Stock that will be outstanding immediately after this offering as shown above is based on 20,946,712 shares outstanding as of February 10, 2022
|
2022-02-15 |
| 2022-03-28 | 2094.67 | 未披露 |
更多>>
From December 31, 2020 to December 31, 2021
Stock-based compensation, common stock issued for services
Options exercised
Warrant exercises
Stock issued in consideration of purchase of subsidiary
Sale of common stock
|
2021-12-31 |
| 2021-11-15 | 2076.67 | 未披露 | 定期报告 | 2021-11-12 |
| 2021-11-15 | 2044.82 | 未披露 |
更多>>
From June 30, 2021 to September 30, 2021
Equity-based compensation - stock issuances to consultants and employees
Sale of common stock, net of transaction costs
|
2021-09-30 |
| 2021-08-23 | 2044.82 | 未披露 | 定期报告 | 2021-08-18 |
| 2021-08-23 | 2029.82 | 未披露 | 定期报告 | 2021-08-05 |
| 2021-07-20 | 1879.82 | 未披露 | 定期报告 | 2021-07-15 |
| 2021-08-12 | 1840.57 | 未披露 |
更多>>
From March 31, 2021 to June 30, 2021
Equity-based compensation - stock issuances to consultants and employees
Sale of common stock, net of transaction costs
|
2021-06-30 |
| 2021-06-23 | 1840.57 | 未披露 | 定期报告 | 2021-06-21 |
| 2021-06-04 | 1810.65 | 未披露 | 定期报告 | 2021-06-01 |
| 2021-04-20 | 1750.35 | 未披露 | 定期报告 | 2021-04-15 |
| 2021-05-17 | 1726.99 | 未披露 |
更多>>
From December 31, 2020 To March 31, 2021
Equity-based compensation - stock issuances to consultants and employees
Warrants exercised
Stock options exercised
Stock issued as consideration for acquisition
Sale of common stock, net of transaction costs
|
2021-03-31 |
| 2021-03-22 | 1726.99 | 未披露 | 定期报告 | 2021-03-22 |
| 2021-03-22 | 1439.31 | 未披露 |
更多>>
from December 31, 2019 to November 18, 2020
Stock-based compensation, common stock issued for services
Sale of common stock & warrants
Warrant exercises
Issuance of commitment shares
|
2020-11-18 |
| 2020-11-13 | 1421.81 | 未披露 |
更多>>
From June 30, 2020 to September 30, 2020
Equity-based compensation - stock and warrant issuances to consultants and employees
Sale of common stock, net of expenses
Exercise of Warrants
|
2020-09-30 |
| 2020-08-13 | 1356.10 | 未披露 | 定期报告 | 2020-08-13 |
| 2020-08-13 | 1344.96 | 未披露 |
更多>>
From March 31, 2020 to June 11, 2020
Sale of common stock, net of expenses
|
2020-06-11 |
| 2020-04-22 | 1062.96 | 未披露 | 定期报告 | 2020-04-16 |
| 2020-05-14 | 1062.96 | 未披露 |
更多>>
From December 31, 2019 to March 31, 2020
Equity-based compensation - stock issuances to consultants and employees
|
2020-03-31 |
| 2020-03-20 | 1047.96 | 未披露 | 定期报告 | 2020-03-20 |
| 2020-03-20 | 1036.84 | 未披露 |
更多>>
From December 31, 2018 to December 31, 2019
Stock-based compensation - common stock issued for services
Sale of Common Stock & Warrants
Exercise of warrants
|
2019-12-31 |
| 2019-11-14 | 1031.84 | 未披露 | 定期报告 | 2019-11-14 |
| 2019-11-14 | 1029.49 | 未披露 |
更多>>
From June 30, 2019 to September 30, 2019
Equity-based compensation - stock issuances to consultants
Exercise of warrants
|
2019-09-30 |
| 2019-08-13 | 1024.24 | 未披露 |
更多>>
From March 31, 2019 to June 30, 2019
Equity-based compensation - stock issuances to consultants
Exercise of warrants
|
2019-06-30 |
| 2019-07-08 | 1022.37 | 未披露 | 定期报告 | 2019-06-25 |
| 2019-05-13 | 1021.96 | 未披露 | 定期报告 | 2019-05-13 |
| 2019-05-13 | 1016.88 | 未披露 |
更多>>
From December 31, 2018 to March 31, 2019
Equity-based compensation - stock issuances to consultants
Sale of Common Stock & Warrants
Exercise of warrants
|
2019-03-31 |
| 2019-03-22 | 1014.38 | 未披露 | 定期报告 | 2019-03-19 |
| 2019-02-12 | 722.90 | 未披露 | 定期报告 | 2019-02-11 |
| 2019-02-19 | 686.25 | 未披露 |
更多>>
from December 31, 2017 to December 31, 2018
Equity-based compensation - stock granted for Performance Bonus Plan cancellation
Equity-based compensation - stock and warrants granted on IPO
Equity-based compensation - stock issuances to consultants
Sale of Common Stock & Warrants
Stock and warrants issued in connection with debt settlements
Conversion of convertible notes on upon IPO
Conversion of June 2018 Senior Note
Exercise of warrants
|
2018-12-31 |
| 2018-11-14 | 655.62 | 未披露 |
更多>>
from December 31, 2017 to September 30, 2018
Equity-based compensation – stock granted for Performance Bonus Plan cancellation
Equity-based consideration – stock and warrants granted on IPO
Sale of common stock and warrants in IPO
Stock stock and warrants issued in connection with debt settlements
Conversion of convertible notes payable on IPO
|
2018-09-30 |
| 2018-09-10 | 655.62 | 未披露 | 定期报告 | 2018-09-06 |
| 2018-07-30 | 653.82 | 未披露 | 定期报告 | 2018-07-27 |
| 2018-06-11 | 326.80 | 未披露 | 定期报告 | 2018-03-31 |
| 2018-01-26 | 547.49 | 未披露 | 定期报告 | 2018-01-26 |
| 2018-04-16 | 499.45 | 未披露 | 定期报告 | 2017-12-31 |
| 2017-09-07 | 406.85 | 未披露 | 定期报告 | 2017-06-30 |
a 1-for-25 reverse stock split of its common stock
The underwriter exercised the warrants to cause the company to issue 9,215,675 shares of common stock
From June 30, 2025 to September 30, 2025
Equity-based compensation – stock issuances to a vendor and vesting to employee
Net proceeds from sale of common stock
Exercise of warrants, net of expenses
From March 31, 2025 to June 30, 2025
Net proceeds from sale of common stock
Exercise of warrants, net of expenses
Common Stock offered 5,341,200 shares by the company
From January 1, 2025 to March 31, 2025
Equity-based compensation - stock issuances to a vendor and vesting to employee
Net proceeds from sale of common stock
From December 31, 2023 to December 31, 2024
Stock-based compensation, common stock issued for services
Issuance of commitment shares
Sale of common stock
Warrant exercises
From June 30, 2024 to September 30, 2024
Equity-based compensation – stock issuances to consultants and employees
Sale of common stock, net of transaction costs
From March 31, 2024 to June 30, 2024
Sale of common stock, net of transaction costs
From December 31, 2023 to March 31, 2024
Exercise of warrants
From December 31, 2022 to December 31, 2023
Issuance of commitment shares
Redemption of fractional shares
Stock-based compensation, common stock issued for services
Warrant exercises
Sale of common stock
From June 30, 2023 to September 30, 2023
Redemption of fractional shares
Sale of common stock, net of transaction costs
Adial Pharmaceuticals, Inc. announced that it will effect a 1-for-25 reverse stock split (“reverse split”) of its common stock, par value $0.001 per share (“Common Stock”), that will become effective on August 4, 2023 at 11:59 p.m. Eastern Time.
From December 31, 2022 to March 31, 2023
Sale of common stock, net of transaction costs
common stock offered 1,829,269 shares by the company
From December 31, 2021 to December 31, 2022
Warrant exercises
Sale of common stock
Stock-based compensation, common stock issued for services
From March 31, 2022 to June 30, 2022
Equity-based compensation - stock issuances to consultants and employees
Warrants exercised
From December 31, 2021 to March 31, 2022
Equity-based compensation - stock issuances to consultants and employees
Sale of common stock and warrants, net of transaction costs
1.Securities offered by 2,322,250 shares of Common Stock
2.The number of shares of Common Stock that will be outstanding immediately after this offering as shown above is based on 20,946,712 shares outstanding as of February 10, 2022
From December 31, 2020 to December 31, 2021
Stock-based compensation, common stock issued for services
Options exercised
Warrant exercises
Stock issued in consideration of purchase of subsidiary
Sale of common stock
From June 30, 2021 to September 30, 2021
Equity-based compensation - stock issuances to consultants and employees
Sale of common stock, net of transaction costs
From March 31, 2021 to June 30, 2021
Equity-based compensation - stock issuances to consultants and employees
Sale of common stock, net of transaction costs
From December 31, 2020 To March 31, 2021
Equity-based compensation - stock issuances to consultants and employees
Warrants exercised
Stock options exercised
Stock issued as consideration for acquisition
Sale of common stock, net of transaction costs
from December 31, 2019 to November 18, 2020
Stock-based compensation, common stock issued for services
Sale of common stock & warrants
Warrant exercises
Issuance of commitment shares
From June 30, 2020 to September 30, 2020
Equity-based compensation - stock and warrant issuances to consultants and employees
Sale of common stock, net of expenses
Exercise of Warrants
From March 31, 2020 to June 11, 2020
Sale of common stock, net of expenses
From December 31, 2019 to March 31, 2020
Equity-based compensation - stock issuances to consultants and employees
From December 31, 2018 to December 31, 2019
Stock-based compensation - common stock issued for services
Sale of Common Stock & Warrants
Exercise of warrants
From June 30, 2019 to September 30, 2019
Equity-based compensation - stock issuances to consultants
Exercise of warrants
From March 31, 2019 to June 30, 2019
Equity-based compensation - stock issuances to consultants
Exercise of warrants
From December 31, 2018 to March 31, 2019
Equity-based compensation - stock issuances to consultants
Sale of Common Stock & Warrants
Exercise of warrants
from December 31, 2017 to December 31, 2018
Equity-based compensation - stock granted for Performance Bonus Plan cancellation
Equity-based compensation - stock and warrants granted on IPO
Equity-based compensation - stock issuances to consultants
Sale of Common Stock & Warrants
Stock and warrants issued in connection with debt settlements
Conversion of convertible notes on upon IPO
Conversion of June 2018 Senior Note
Exercise of warrants
from December 31, 2017 to September 30, 2018
Equity-based compensation – stock granted for Performance Bonus Plan cancellation
Equity-based consideration – stock and warrants granted on IPO
Sale of common stock and warrants in IPO
Stock stock and warrants issued in connection with debt settlements
Conversion of convertible notes payable on IPO